All In Biotech

Drug Trial Radar · NCT06715670

A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants

A Phase I, Randomized, Open-label, Single-dose, Four-period, Four-treatment, Cross-over Study to Assess the Pharmacokinetics of Zibotentan in Healthy Non-Asian and Japanese Participants

Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Dec 5, 2024

Primary completion

Feb 28, 2025

Study completion Feb 28, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aim to assess the Pharmacokinetics of Zibotentan in Healthy Non-Asian and Japanese Participants.

Conditions

  • Liver Cirrhosis

Interventions

  • ZibotentanDrug

    Participant will receive 4 different single doses of zibotentan on Day 1 of each treatment period orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under concentration-time curve from time 0 to infinity (AUCinf)Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)
  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)
  3. Maximum observed drug concentration (Cmax)Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.